MDGL
Madrigal Pharmaceuticals, Inc.
546.89
1 x 544.35
1 x 531.08
bid
ask
+
17.05
3.22%
1 @ 04:00 PM
543.50 -3.39 (0.62%)
Ytd -6.09%
1y 63.45%
522.49
day range
547.98
267.56
52 week range
602.83
Open 531.19 Prev Close 529.84 Low 522.49 High 547.98 Mkt Cap 12.55B
Vol 344.96K Avg Vol 379.77K EPS -12.85 P/E N/A Forward P/E 42.75
Beta -0.96 Short Ratio 10.59 Inst. Own 104.72% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-30 50-d Avg 466.78 200-d Avg 446.91 1yr Est 668.57
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 0 N/A N/A N/A
2026-02-19 2025-12 0.04 N/A -2.61 -6.00%
2025-11-04 2025-09 0 N/A -3.1 -156.57%
2025-08-05 2025-06 0 N/A 1.58 45.40%
2025-05-01 2025-03 0 N/A 0.3 8.29%
2025-02-26 2024-12 0 N/A 1.41 34.22%
Upgrade / Downgrade
Date Firm Action From To
2026-02-20 B of A Securities Upgrade Neutral Neutral
2026-01-28 Barclays Upgrade Overweight
2026-01-20 Citizens Upgrade Market Outperform Market Outperform
2025-12-19 Piper Sandler Upgrade Overweight Overweight
2025-12-11 B. Riley Securities Upgrade Buy Buy
2025-11-21 HC Wainwright & Co. Upgrade Buy Buy
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
Date Name Relation Quantity Description
2025-08-19 BAKER BROS ADVISORS, L.P. Unknown 0.00 Purchase
2025-03-12 CRAVES FREDERICK B Director 383.55K Conversion of Exercise of derivative security
2026-03-05 DIER MARDI C Chief Financial Officer 12.49K Sale
2026-01-08 FRIEDMAN PAUL A Director 842.70K Conversion of Exercise of derivative security
2026-03-05 HUNTSMAN CAROLE A Officer 12.69K Sale
2026-03-05 KELLEY SHANNON T General Counsel 12.14K Sale
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Baker Bros. Advisors, LP 2.14M 1.17B 9.34%
2025-12-30 RTW Investments LP 1.99M 1.09B 8.69%
2025-12-30 Vanguard Group Inc 1.81M 989.27M 7.89%
2025-12-30 Avoro Capital Advisors LLC 1.81M 988.50M 7.88%
2025-12-30 PAULSON & CO. INC. 1.71M 933.83M 7.44%
2025-12-30 Blackrock Inc. 1.64M 899.50M 7.17%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 574.39K 314.13M 2.50%
2026-01-30 iShares Trust-iShares Russell 2000 ETF 443.13K 242.34M 1.93%
2025-12-30 JANUS INVESTMENT FUND-Janus Henderson Forty Fund 429.42K 234.84M 1.87%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 412.29K 225.48M 1.80%
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 398.13K 217.73M 1.74%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund 200.67K 109.74M 0.87%
Split
Split Date
1 : 35 2016-07-25